R

Reata Pharmaceuticals Inc
F:2R3

Watchlist Manager
Reata Pharmaceuticals Inc
F:2R3
Watchlist
Price: 161 EUR Market Closed
Market Cap: 6B EUR

Operating Margin
Reata Pharmaceuticals Inc

-1 455.1%
Current
-5 162%
Average
6%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-1 455.1%
=
Operating Profit
-341.7m
/
Revenue
23.5m

Operating Margin Across Competitors

No Stocks Found

Reata Pharmaceuticals Inc
Glance View

Reata Pharmaceuticals Inc., based in Plano, Texas, has crafted its narrative around the relentless pursuit of innovative therapies targeting serious and life-threatening diseases. The company's story began with a profound commitment to addressing rare genetic diseases affecting the central nervous system—conditions often overlooked by larger pharmaceutical enterprises due to their complexity and limited patient populations. Reata's strategy revolves around leveraging its expertise in molecular biology to develop unique therapeutic solutions that modulate biochemical pathways. Its lead compounds, such as Omaveloxolone, are designed to combat oxidative stress—an underlying pathophysiological factor in many neurological disorders. The company’s business model finds equilibrium between high-stakes innovation and strategic partnerships. By targeting rare diseases with niche but under-penetrated markets, Reata can potentially command premium pricing for its treatments, often under the auspices of orphan drug status which provides regulatory and market exclusivity advantages. Beyond its own pipeline advancements, Reata also extends its financial reach through strategic alliances with major industry players, enhancing its capital influx and accelerating drug development. The complex tapestry of cutting-edge science, strategic foresight, and the ability to navigate regulatory landscapes paints Reata Pharmaceuticals as not only a beacon of hope for patients but also a dynamic player in the biopharmaceutical sector.

2R3 Intrinsic Value
Not Available
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-1 455.1%
=
Operating Profit
-341.7m
/
Revenue
23.5m
What is the Operating Margin of Reata Pharmaceuticals Inc?

Based on Reata Pharmaceuticals Inc's most recent financial statements, the company has Operating Margin of -1 455.1%.

Back to Top